Medizinische Hochschule Hannover

Twincore, Zentrum Fur Experimentelle Und Klinische Infektionsforschung Gmbh

Technische Universitát Dresden

Helmholtz-zentrum Fur Infektionsforschung Gmbh

Centre National De La Recherche Scientifique

Universitéde Strasbourg

Twincore Gmbh

Sibylle Haid

Elisabeth Davioud-Charvet

Thomas Pietschmann

Martin Messerle

Hans-Peter Prochnow

Don Antoine Lanfranchi

Mark Brönstrup

Gesine Hansen

Thomas Schulz

Lars Kaderali

Sergej Franz

Dominic Howard Banda

Nv Suryanarayana Birudukota

Chris Lauber

Christine Laqmani-Goffinet

Daniel Todt

Sebastian Blockus

Martin Wetzke

Juliane Gentzsch

Christina Grethe

Svenja Sake

Jessica Rückert

Xavier Benlloch-Martin

Mourad Elhabiri

The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.

Diagnostics and therapy for human respiratory syncytial virus

The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g. for treating an infectious disease caused by an infection with RSV, KSHV, CMV, DENV, CHIKV, TBEV, VSV, ZIKV and/or HCV.

Labyrinthopeptins as anti-viral agents

Growing community of inventors

Hannover, Germany

Sibylle Haid